Opinion|Videos|July 23, 2024
Preparation of RSV Vaccines
Focusing on the preparation of RSV vaccines, Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, provides detailed insights on the differences between the adjuvanted and nonadjuvanted vaccines.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- There are currently two RSV vaccines available, adjuvanted and non-adjuvanted. How do these vaccines compare based on their indicated patient populations, preparation, dosing, and administration?
Advertisement
Related to this article
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
The FDA expanded approval of talazoparib plus enzalutamide to HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer following a significant radiographic PFS benefit in TALAPRO-3.
Pharmacists can help care for patients receiving breast cancer endocrine therapy by identifying fracture risk early and supporting appropriate bone-directed treatment throughout survivorship.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer
2
Medicare GLP-1 Bridge Runs Outside Part D and Pharmacy Teams Need a Different Workflow
3
Cystatin C and the Future of Kidney Function Assessment
4
GLP-1 RAs, Finerenone, and CKD: Key Data From Kidney Week 2026
5